Patents Examined by Laura L. Stockton
  • Heterobifunctional compounds with improved specificity
    Patent number: 11505560
    Abstract: Disclosed are heterobifunctional compounds that effectuate selective degradation of a target protein, and which include a targeting ligand that binds a target protein and at least one other protein, a ligand that binds an E3 ubiquitin ligase or a component of E3 ubiquitin ligase, and a specificity modulating linker that links the first ligand and the second ligand. Pharmaceutical compositions containing the compounds, and methods of using and making the compounds are also disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: November 22, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Radoslaw P. Nowak, Eric S. Fischer, Nathanael S. Gray, Tinghu Zhang, Zhixiang He, Brian Groendyke
  • Fused thiophene derivatives and their uses
    Patent number: 11492347
    Abstract: The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 8, 2022
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoît De Chassey, Peter Machin, Roberta Lanaro, Calum MacLeod, Karine Fabienne Malagu, Nicolas Proisy, David Robert Vesey, Paul Colin Michael Winship, Mark Chambers
  • Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
    Patent number: 11492335
    Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: November 8, 2022
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Su Bin Choi, Dong Hoon Kim, Sol Park, Eun Hye Jung, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
  • Derivatives of piperlongumine and uses thereof
    Patent number: 11485725
    Abstract: The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: November 1, 2022
    Assignee: Auransa Inc.
    Inventors: Andrew Asher Protter, Michael John Green, Hak Jin Chang, Son Minh Pham, Sarvajit Chakravarty, Gregory R. Luedtke, Pek Yee Lum
  • Hydroxyethylamine-based piperazine compounds, and methods of producing and using the same for treating disease
    Patent number: 11485714
    Abstract: Disclosed herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, related pharmaceutical compositions, and methods for using the same to treat parasitic diseases.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: November 1, 2022
    Assignee: National Institute of Immunology
    Inventors: Brijesh Rathi, Prakasha Kempaiah, Agam P. Singh, Snigdha Singh, Yash Gupta, Neha Sharma, Poonam, Ravi Durvsula
  • Emopamil binding protein binding agent and use thereof
    Patent number: 11479547
    Abstract: Required are: a compound having high affinity for an emopamil binding protein; and a method for activating or inhibiting the emopamil binding protein, using such a compound. According to the present invention, provided is an emopamil binding protein binding agent comprising an alkyl ether derivative represented by the following formula [1] or a salt thereof: wherein R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n, which are the same or different, each represent an integer of 1 to 6.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 25, 2022
    Assignee: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Takeaki Yano, Kaori Miyamoto, Koichi Saito
  • OX2R compounds
    Patent number: 11479560
    Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: October 25, 2022
    Inventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
  • Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
    Patent number: 11472802
    Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 18, 2022
    Assignee: Array BioPharma Inc.
    Inventors: Shane M. Walls, Li Ren, Ginelle A. Ramann, David A. Moreno, Andrew T. Metcalf, Elizabeth A. McFaddin, Gabrielle R. Kolakowski, James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn
  • Fused imidazole derivatives as IL-17 modulators
    Patent number: 11472794
    Abstract: A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 18, 2022
    Assignee: UCB Biopharma SRL
    Inventors: Gareth Neil Brace, Rose Elizabeth Bardell-Cox, Gregory Foulkes, James Richard Frost, Helen Tracey Horsley, Elizabeth Pearl Jones, Fabien Claude Lecomte, James Thomas Reuberson, Monika-Sarah Elizabeth Dorothea Schulze, Richard David Taylor, Wei Tsung Yau, Zhaoning Zhu
  • OX2R compounds
    Patent number: 11472813
    Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
    Type: Grant
    Filed: September 27, 2020
    Date of Patent: October 18, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
  • Heterocyclic compound
    Patent number: 11459325
    Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: October 4, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuta Tanaka, Tomohiro Ohashi, Zenichi Ikeda, Yuta Tanaka, Florian Pünner, Takeshi Yamamoto, Keiko Kakegawa, Fumiaki Kikuchi, Nao Morishita, Takahito Kasahara, Masaki Seto, Minoru Nakamura, Kazuaki Takami, Masataka Murakami, Masaki Daini, Satoshi Mikami, Minoru Sasaki
  • Antibacterial compounds
    Patent number: 11459296
    Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-?-lactamase inhibitors.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: October 4, 2022
    Assignee: INFEX Therapeutics Limited
    Inventors: Ian Cooper, David Orr, Andrew Wilkinson, Jonathan Finlayson, Adam Bunt, Pia Appelqvist, Hans Wallberg, Fredrik Wångsell
  • Biguanide derivatives and their rearrangement products for use in the treatment of cancer
    Patent number: 11440906
    Abstract: The present disclosure relates to biguanide derivatives of formula (I) and their rearrangement products. The present disclosure also relates to the use of these compounds in a method for treating cancer, in particular melanoma.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 13, 2022
    Assignees: Centre National de la Recherche Scientifique, INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'Azur
    Inventors: Rachid Benhida, Stephane Rocchi, Cyril Ronco, Emile Jaune, Oleksandr Grytsai, Nedra Tekaya
  • Kinase inhibitors
    Patent number: 11427591
    Abstract: A DDR1 inhibitor compound can have a structure of Formula A, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center, ring A is a ring structure; ring B is a ring structure; the X1, X2, X3, X4, and X5 are each independently a carbon or a hetero atom with or without a substituent; the Y is a linker; and each R1, R2, R3, R5, and R6 is independently a substituent; and each n is an integer, such as from 0 to the maximum number of allowed substituents on the linker or ring, wherein R5 and/or R6 is optionally nothing.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: August 30, 2022
    Assignee: Insilico Medicine IP Limited
    Inventors: Aleksandr M. Aliper, Yan Ivanenkov, Daniil Polykovskiy, Victor Terentiev, Aleksandrs Zavoronkovs
  • Carbon capture, storage, and recycling compositions
    Patent number: 11414445
    Abstract: The invention relates to carbon dioxide dioxaphosphetane compositions, including solid carbon dioxide dioxaphosphetane compositions. The invention includes compositions and methods for the capture, storage, and recycling of carbon, including methods of boric acid catalyzed reduction of carbonates in aqueous media and the use of phosphate solutions for capture and recycling of carbon.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 16, 2022
    Assignee: OAKLAND CITY UNIVERSITY, FOUNDED BY GENERAL BAPTISTS, INC.
    Inventor: Barnabas Otoo
  • P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
    Patent number: 11414444
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 16, 2022
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Xiang Li, Yuanyuan Jiang, Kai Liu, Yeming Wang, Liying Zhou, Yanan Liu, Ning Shao, Fengping Xiao
  • Tropomyosin-related kinase (TRK) inhibitors
    Patent number: 11406644
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: August 9, 2022
    Assignee: Genzyme Corporation
    Inventors: John L. Kane, Jr., Gloria Matthews, Markus Metz, Michael Kothe, Jinyu Liu, Andrew Scholte
  • Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues
    Patent number: 11407752
    Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues, the use thereof and the preparation thereof.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: August 9, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Jia Zhou, Pei-Yong Shi, Jimin Xu, Xuping Xie
  • Anti-bacterial heterocyclic compounds and their synthesis
    Patent number: 11401277
    Abstract: The invention relates to compounds of Formula I and Formula (B) along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof. These compounds are useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: August 2, 2022
    Assignee: BUGWORKS RESEARCH, INC.
    Inventors: Shahul Hameed Peer Mohamed, Nagakumar Bharatham, Nainesh Katagihallimath, Sreevalli Sharma, Radha Nandishaiah, Vasanthi Ramachandran
  • Bicyclic heteroaryl derivatives and preparation and uses thereof
    Patent number: 11401249
    Abstract: The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 2, 2022
    Assignee: XWPHARMA LTD.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Wei Zhou